This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wilson, P. W. F. Articles by Grundy, S. M. Search for Related Content PubMed PubMed Citation Articles by Wilson, P. W. F. Articles by Grundy, S. M. Pubmed/NCBI databases Medline Plus Health Information Metabolic Syndrome Related Collections Lipids Obesity Clinical Studies Epidemiology

(Circulation. 2003;108:1422.)
© 2003 American Heart Association, Inc.

Clinician Update

The Metabolic Syndrome

Practical Guide to Origins and Treatment: Part I

Peter W. F. Wilson, MD; Scott M. Grundy, MD, PhD

From the Framingham Heart Study of the National Heart, Blood, and Lung Institute, Boston, Mass.

Correspondence to Boston University School of Medicine, 715 Albany St, Evans 204, Boston, MA 02118. E-mail pwilson@bu.edu

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
The metabolic syndrome (MetS), a cluster of metabolic abnormalities with insulin resistance as a major characteristic, has gone by several names over the past two decades. The diagnostic criteria proposed by the Adult Treatment Program III (ATP III) of the National Cholesterol Education Program (NCEP) have led to greater awareness of the components and treatment strategies.¹ Five diagnostic traits are listed in the ATP III version of the MetS (Table; referred to as the "metabolic syndrome"), and the presence of any 3 of these factors is considered sufficient for diagnosis. This practical review will consider each in turn, providing advice for cardiologists, internists, and other health care providers who are diagnosing and treating persons with the syndrome in an effort to prevent a variety of clinical outcomes.

View this table: [in this window] [in a new window]   Diagnostic Criteria for the Metabolic Syndrome

The major adverse consequence of the MetS is cardiovascular disease (CVD). Several of the metabolic abnormalities associated with the syndrome, in fact, are CVD risk factors. One of these abnormalities, insulin resistance, also predisposes to the development of type 2 diabetes mellitus (T2DM).

In age-adjusted estimates from the National Health and Nutrition Examination Survey III in 1998 to 1994, approximately 24% of adult Americans had 3 of the 5 MetS criteria. Key determinants of greater prevalence were age and ethnicity. Prevalence rates were highest in Mexican Americans and were successively lower in white, African American and other racial groups.² These published estimates included persons with diabetes mellitus who had met the 1998 fasting glucose criteria . . . [Full Text of this Article]

This article has been cited by other articles:

				L. Chatzi, E. Plana, V. Daraki, P. Karakosta, D. Alegkakis, C. Tsatsanis, A. Kafatos, A. Koutis, and M. Kogevinas Metabolic Syndrome in Early Pregnancy and Risk of Preterm Birth Am. J. Epidemiol., October 1, 2009; 170(7): 829 - 836. [Abstract] [Full Text] [PDF]

				K. Hotta, M. Hosaka, A. Tanabe, and T. Takeuchi Secretogranin II binds to secretogranin III and forms secretory granules with orexin, neuropeptide Y, and POMC J. Endocrinol., July 1, 2009; 202(1): 111 - 121. [Abstract] [Full Text] [PDF]

				S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, D. M. Mancini, K. Michl, et al. 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation J. Am. Coll. Cardiol., April 14, 2009; 53(15): e1 - e90. [Full Text] [PDF]

				2005 WRITING COMMITTEE MEMBERS, S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, D. M. Mancini, et al. 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation Circulation, April 14, 2009; 119(14): e391 - e479. [Full Text] [PDF]

				J. S. Gilbert and M. J. Nijland Sex differences in the developmental origins of hypertension and cardiorenal disease Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2008; 295(6): R1941 - R1952. [Abstract] [Full Text] [PDF]

				T. Yanagiya, A. Tanabe, A. Iida, S. Saito, A. Sekine, A. Takahashi, T. Tsunoda, S. Kamohara, Y. Nakata, K. Kotani, et al. Association of single-nucleotide polymorphisms in MTMR9 gene with obesity Hum. Mol. Genet., December 15, 2007; 16(24): 3017 - 3026. [Abstract] [Full Text] [PDF]

				C A Daly, P Hildebrandt, M Bertrand, R Ferrari, W Remme, M Simoons, K M Fox, and on behalf of the EUROPA investigators Adverse prognosis associated with the metabolic syndrome in established coronary artery disease: data from the EUROPA trial Heart, November 1, 2007; 93(11): 1406 - 1411. [Abstract] [Full Text] [PDF]

				C. Schindler Review: The metabolic syndrome as an endocrine disease: is there an effective pharmacotherapeutic strategy optimally targeting the pathogenesis? Therapeutic Advances in Cardiovascular Disease, October 1, 2007; 1(1): 7 - 26. [Abstract] [PDF]

				A. Stavropoulos-Kalinoglou, G. S Metsios, Y. Koutedakis, A. M Nevill, K. M Douglas, A. Jamurtas, J. J C S V. van Zanten, M. Labib, and G. D Kitas Redefining overweight and obesity in rheumatoid arthritis patients Ann Rheum Dis, October 1, 2007; 66(10): 1316 - 1321. [Abstract] [Full Text] [PDF]

				J. Mukuddem-Petersen, M. B Snijder, R. M van Dam, J. M Dekker, L. M Bouter, C. D. Stehouwer, R. J Heine, G. Nijpels, and J. C Seidell Sagittal abdominal diameter: no advantage compared with other anthropometric measures as a correlate of components of the metabolic syndrome in elderly from the Hoorn Study. Am. J. Clinical Nutrition, November 1, 2006; 84(5): 995 - 1002. [Abstract] [Full Text] [PDF]

				L. A. Yancura, C. M. Aldwin, M. R. Levenson, and A. Spiro III Coping, affect, and the metabolic syndrome in older men: how does coping get under the skin? J. Gerontol. B. Psychol. Sci. Soc. Sci., September 1, 2006; 61(5): P295 - P303. [Abstract] [Full Text] [PDF]

				R. Kahn, J. Buse, E. Ferrannini, and M. Stern The Metabolic Syndrome: Time for a Critical Appraisal: Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care, September 1, 2005; 28(9): 2289 - 2304. [Abstract] [Full Text] [PDF]

				R. A. Hegele and R. L. Pollex Genetic and physiological insights into the metabolic syndrome Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2005; 289(3): R663 - R669. [Abstract] [Full Text] [PDF]

				Y. Song, P. M. Ridker, J. E. Manson, N. R. Cook, J. E. Buring, and S. Liu Magnesium Intake, C-Reactive Protein, and the Prevalence of Metabolic Syndrome in Middle-Aged and Older U.S. Women Diabetes Care, June 1, 2005; 28(6): 1438 - 1444. [Abstract] [Full Text] [PDF]

				G D Kolovou, K K Anagnostopoulou, and D V Cokkinos Pathophysiology of dyslipidaemia in the metabolic syndrome Postgrad. Med. J., June 1, 2005; 81(956): 358 - 366. [Abstract] [Full Text] [PDF]

				C. Irace, C. Cortese, E. Fiaschi, C. Carallo, G. Sesti, E. Farinaro, and A. Gnasso Components of the Metabolic Syndrome and Carotid Atherosclerosis: Role of Elevated Blood Pressure Hypertension, April 1, 2005; 45(4): 597 - 601. [Abstract] [Full Text] [PDF]

				F. Angelico, M. Del Ben, R. Conti, S. Francioso, K. Feole, S. Fiorello, M. G. Cavallo, B. Zalunardo, F. Lirussi, C. Alessandri, et al. Insulin Resistance, the Metabolic Syndrome, and Nonalcoholic Fatty Liver Disease J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1578 - 1582. [Abstract] [Full Text] [PDF]

				J. A Armitage, I. Y Khan, P. D Taylor, P. W Nathanielsz, and L. Poston Developmental programming of the metabolic syndrome by maternal nutritional imbalance: how strong is the evidence from experimental models in mammals? J. Physiol., December 1, 2004; 561(2): 355 - 377. [Abstract] [Full Text] [PDF]

				S. Sinha, G. Perdomo, N. F. Brown, and R. M. O'Doherty Fatty Acid-induced Insulin Resistance in L6 Myotubes Is Prevented by Inhibition of Activation and Nuclear Localization of Nuclear Factor {kappa}B J. Biol. Chem., October 1, 2004; 279(40): 41294 - 41301. [Abstract] [Full Text] [PDF]

				O. C. Marroquin, K. E. Kip, D. E. Kelley, B. D. Johnson, L. J. Shaw, C. N. Bairey Merz, B. L. Sharaf, C. J. Pepine, G. Sopko, S. E. Reis, et al. Metabolic Syndrome Modifies the Cardiovascular Risk Associated With Angiographic Coronary Artery Disease in Women: A Report From the Women's Ischemia Syndrome Evaluation Circulation, February 17, 2004; 109(6): 714 - 721. [Abstract] [Full Text] [PDF]

				P. C. Deedwania Metabolic Syndrome and Vascular Disease: Is Nature or Nurture Leading the New Epidemic of Cardiovascular Disease? Circulation, January 6, 2004; 109(1): 2 - 4. [Full Text] [PDF]